Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Subscribe To Our Newsletter & Stay Updated